'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Next-Stage Strategies Formulated
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.
